HY
Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
4.20 € +3.70% (+0.15 €)
1M -2.27%
Market Cap 117.6M €
P/E Ratio -
Div. Yield -
ROE 22.88%
Piotroski F-Score Weak
1/9Valuation
22 /100
Expensive P/B 4.44x
P/S 14.81x
EV/FFO N/A
Growth
78 /100
Growing Book val. growth 21.10%
Rev. growth 34.67%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 85.75%
Gross margin 95.23%
FCF margin 88.08%
Quality
3 /100
Poor ROA 18.99%
ROIC 25.14%
Asset turnover 0.24x
Debt
100 /100
Low Current ratio 3.89x
Debt/Equity 0.06x
Debt/Assets N/A
Stability
39 /100
Moderate EPS volatility 44.36%
Beta 0.64x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o HYL.BR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stijn Van Rompay
Employees
55
Headquarters
Liège